Article
Pharmacology & Pharmacy
Leonor Corte-Real, Ana Rita Bras, Adhan Pilon, Nuno Mendes, Ana Sofia Ribeiro, Tiago D. Martins, Jose Paulo S. Farinha, M. Conceicao Oliveira, Fatima Gartner, M. Helena Garcia, Ana Preto, Andreia Valente
Summary: The need for new therapeutic approaches for triple-negative breast cancer is clinically relevant. A new family of ruthenium(II) organometallic complexes was synthesized with the aim of enhancing cancer cell uptake through a multi-targeting approach. These compounds showed promising anti-cancer effects against triple-negative breast cancer cells in experimental conditions.
Article
Chemistry, Medicinal
Nazia Nayeem, Arefa Yeasmin, Samantha N. Cobos, Ali Younes, Karen Hubbard, Maria Contel
Summary: The study evaluated the effects of a water-soluble organometallic ruthenium compound Ru-IM (1) on TNBC cell lines derived from patients of European and African ancestry, showing high cytotoxicity and potential anti-metastatic and anti-angiogenic properties. The compound was found to inhibit protein expression of cytokine M-CSF involved in the PI3/AKT pathway, and demonstrated a p53-independent mechanism of action.
Article
Biochemistry & Molecular Biology
Najwa Mansour, Kikki Bodman-Smith, Rony S. Khnayzer, Costantine F. Daher
Summary: The photoactivatable Ru(II) complex 1 exhibited promising anticancer activity against triple negative adenocarcinoma MDA-MB-231 cells. Upon photoactivation, complex 1 showed time-dependent cytotoxic activity, inducing cell apoptosis and activating intrinsic and extrinsic pathways while inhibiting MAPK and PI3K pathways. The study suggests that complex 1 is a potent multimechanistic photoactivatable chemotherapeutic drug with potential for targeted cancer chemotherapy.
CHEMICO-BIOLOGICAL INTERACTIONS
(2021)
Article
Oncology
Jiaojiao Deng, Sophia B. Chernikova, Yuelong Wang, Mirna L. Rodriguez, Stephanie J. Andersen, Maxine C. Umeh-Garcia, Bryanna O. Godfrey, Saman S. Ahmadian, Wolf-Nicolas Fischer, Kerry J. Koller, Bernd Jandeleit, Gordon M. Ringold, Melanie Hayden Gephart
Summary: Metastasis to the central nervous system from breast cancer, especially triple-negative breast cancer, presents a significant clinical challenge due to limited treatment options and rapidly fatal outcomes. Novel therapeutic options that can effectively target brain metastasis and leptomeningeal spread are urgently needed in order to improve patient outcomes.
MOLECULAR CANCER THERAPEUTICS
(2021)
Article
Chemistry, Inorganic & Nuclear
Mingxiao Shao, Meimei Yao, Xicheng Liu, Chao Gao, Weiyan Liu, Jinghang Guo, Jiawen Zong, Xinzhuo Sun, Zhe Liu
Summary: Iridium(III) complexes with a half-sandwiched structure have shown potential as organometallic antitumor agents, entering tumor cells in an energy-dependent manner and accumulating in lysosomes to induce apoptosis. These complexes have demonstrated promising antitumor activity with minimal side effects, making them a candidate for the treatment of malignant tumors.
INORGANIC CHEMISTRY
(2021)
Article
Chemistry, Multidisciplinary
Li-weny Shen, Xiu-xing Jiang, Zhi-qiang Li, Jie Li, Mei Wang, Guan-fei Jia, Xin Ding, Ling Lei, Qi-hai Gong, Ning Gao
Summary: Inhibition of autophagy/mitophagy by cepharanthine synergistically induced apoptosis in triple negative breast cancer cells along with epirubicin, demonstrating a promising therapeutic strategy for the treatment of breast cancer.
ACTA PHARMACOLOGICA SINICA
(2022)
Article
Pharmacology & Pharmacy
Leilei Gou, Grace Gar-Lee Yue, Julia Kin -Ming Lee, Pema Tenzin Puno, Clara Bik-San Lau
Summary: Eriocalyxin B (Eri B), an ent-kaurane diterpenoid, inhibits migration and adhesion in triple negative breast cancer (TNBC) cells, reduces ALDH1A1 expression and colony formation in cancer stem cell (CSC) enriched MDA-MB-231 cells. Eri B demonstrates potent anti-metastatic efficacy in breast tumor-bearing mouse models. Gut microbiome analysis reveals changes in diversity and composition of microbiome after Eri B treatment, potentially contributing to its anti-cancer effects.
BIOCHEMICAL PHARMACOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Shengli Dong, Hassan Yousefi, Isabella Van Savage, Samuel C. Okpechi, Maryl K. Wright, Margarite D. Matossian, Bridgette M. Collins-Burow, Matthew E. Burow, Suresh K. Alahari
Summary: Combination therapy with ceritinib and enzalutamide inhibits the growth of AR(+) TNBC cells, while combination therapy with ceritinib and paclitaxel drastically inhibits tumor growth. These findings suggest that combination treatment with these FDA-approved drugs can improve the therapeutic response in both AR-positive and negative breast cancer.
Article
Cell Biology
Marie Winter, Samuel Meignan, Pamela Volkel, Pierre-Olivier Angrand, Valerie Chopin, Nadege Bidan, Robert-Alain Toillon, Eric Adriaenssens, Chann Lagadec, Xuefen Le Bourhis
Summary: The study reveals that TNBC cells become more invasive after chemotherapy, with vimentin potentially playing a role in enhancing tumor aggressiveness.
Review
Biochemistry & Molecular Biology
Han Chen, Jiaping Yang, Yanlong Yang, Jianpeng Zhang, Yao Xu, Xiaoling Lu
Summary: TNBC, accounting for 15% to 20% of all BC cases, is one of the most challenging malignancies to treat, with chemotherapy being the main option. Natural compounds from marine and terrestrial sources have diverse structures and biochemical specificity, providing a compound library for discovering new drugs. Recent research has focused on natural products with strong anti-TNBC activities and their potential mechanisms from 2015 to 2021.
CHEMISTRY & BIODIVERSITY
(2021)
Article
Pharmacology & Pharmacy
Lai Jin, Tiantian Li, Yali Hong, Rongchen Mao, Li Xu, Chao Zhu, Junyu Mu, Jun Zhou, Lihua Pan, Yuhui Que, Yidong Xia, Yuheng Zhang, Shengnan Li
Summary: Nucleotide-binding oligomerization domain (NOD)-like receptor type 2 protein (NLRP2) inhibits NF-KB in breast cancer metastasis and is positively correlated with survival rate and negatively correlated with metastasis potential. Re-expression of NLRP2 inhibits growth and metastasis of TNBC xenograft model. NLRP2 modulates hnRNPK and could be a biomarker for TNBC chemotherapy.
BIOCHEMICAL PHARMACOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Oscar A. Lenis-Rojas, Catarina Roma-Rodrigues, Alexandra R. Fernandes, Andreia Carvalho, Sandra Cordeiro, Jorge Guerra-Varela, Laura Sanchez, Digna Vazquez-Garcia, Margarita Lopez-Torres, Alberto Fernandez, Jesus J. Fernandez
Summary: This study presents the first in vivo research on Ru(II)-polypyridyl complexes against breast cancer, showing promising results with both mono- and dinuclear compounds. Ru1 and Ru2 were able to reduce tumor size significantly at low doses without causing lethality, indicating their potential as chemotherapy agents in breast cancer therapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Chemistry, Inorganic & Nuclear
Oscar A. Lenis-Rojas, M. Paula Robalo, Ana Isabel Tomaz, Alexandra R. Fernandes, Catarina Roma-Rodrigues, Ricardo G. Teixeira, Fernanda Marques, Monica Folgueira, Julian Yanez, Anabel Alba Gonzalez, Martin Salamini-Montemurri, Dawrin Pech-Puch, Digna Vazquez-Garcia, Margarita Lopez Torres, Alberto Fernandez, Jesus J. Fernandez
Summary: Ruthenium(II) complexes, considered as attractive alternatives to platinum-based drugs, demonstrated significant cytotoxicity against breast cancer cells with lower toxicity towards normal cells, possibly through induction of reactive oxygen species and interaction with protein targets.
INORGANIC CHEMISTRY
(2021)
Article
Nanoscience & Nanotechnology
Hana Stepankova, Marcin Swiatkowski, Rafal Kruszynski, Pavel Svec, Hana Michalkova, Vendula Smolikova, Andrea Ridoskova, Zbynek Splichal, Petr Michalek, Lukas Richtera, Pavel Kopel, Vojtech Adam, Zbynek Heger, Simona Rex
Summary: This study focuses on the potential use of coordination compound-based zinc oxide nanoparticles for treating triple negative breast cancer cells. The nanoparticles showed selective cytotoxicity towards TNBrCa cells, affecting their metabolism and morphology leading to cell death. The morphology, size, and zinc content of the nanoparticles appear to be crucial properties for their future therapeutic potential in TNBrCa.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2021)
Article
Nanoscience & Nanotechnology
Sylwia Michlewska, Dagmara Wojkowska, Cezary Watala, Elzbieta Skiba, Paula Ortega, Francisco Javier de la Mata, Maria Bryszewska, Maksim Ionov
Summary: Carbosilane metallodendrimers based on the arene Ru(II) complex (CRD13) and integrated with imino-pyridine surface groups have been investigated as an anticancer agent in a mouse model of triple-negative breast cancer. The dendrimer efficiently enters cells and exhibits selective toxicity for 4T1 cells. In vivo investigations have shown that local injection of CRD13 reduces tumor mass without causing toxicity. ICP analyses have indicated that Ru(II) accumulates in all tested tissues, with a higher content detected in the tumor.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
(2023)
Article
Oncology
Masayoshi Yamaguchi, Satoru Osuka, Tomiyasu Murata, Joe W. Ramos
Summary: Prostate cancer is the second leading cause of cancer-related death in men and currently, there is no effective treatment for metastatic prostate cancer. Regucalcin has been shown to have suppressive effects on various human cancers, and in this study, its involvement in suppressing prostate cancer was investigated. Higher regucalcin expression was associated with prolonged progression-free survival in patients, and overexpression of regucalcin in bone metastatic prostate cancer cells resulted in decreased cell growth and colony formation through various molecular pathways. These findings suggest that regucalcin may be a potential therapeutic target for the treatment of human prostate cancer.
TRANSLATIONAL ONCOLOGY
(2021)
Article
Oncology
Chantal Reina-Ortiz, Michael Constantinides, Alexis Fayd-Herbe-de-Maudave, Jessy Presumey, Javier Hernandez, Guillaume Cartron, Rosana Diez, Isabel Izquierdo, Gemma Azaceta, Luis Palomera, Isabel Marzo, Javier Naval, Alberto Anel, Martin Villalba, David Giraldosa
Summary: The study evaluated the potential of expanded NK cells from two sources combined with mAbs to target primary multiple myeloma cells. Results indicate that umbilical cord blood eNKs are highly cytotoxic against MM cells, while peripheral blood eNKs have significant cytotoxic advantage when combined with daratumumab.
Article
Chemistry, Multidisciplinary
Marta Redrado, Andrea Benedi, Isabel Marzo, Angel L. Garcia-Otin, Vanesa Fernandez-Moreira, M. Concepcion Gimeno
Summary: A new class of emissive cyclometallated Ir-III-Au-I complexes with a bis(diphenylphosphino) methanide bridging ligand was synthesized successfully. These complexes showed different bioactivity in A549 lung carcinoma cells versus endothelial cells, mainly affecting the mitochondrial and lysosomal distribution within the cells.
CHEMISTRY-A EUROPEAN JOURNAL
(2021)
Review
Pharmacology & Pharmacy
Alfonso Serrano-del Valle, Chantal Reina-Ortiz, Andrea Benedi, Alberto Anel, Javier Naval, Isabel Marzo
Summary: Developing new therapies targeting cell cycle regulation and mitosis has shown potential, despite many being discontinued during clinical trials. Future efforts could focus on increasing cell death signals, targeting senescent cells, and promoting antitumor immune response to enhance the efficacy of these treatments.
BIOCHEMICAL PHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Marta Redrado, Andrea Benedi, Isabel Marzo, M. Concepcion Gimeno, Vanesa Fernandez-Moreira
Summary: Photodynamic therapy (PDT) is a cancer treatment method with great potential for improvement, with a focus on developing photosensitizers (PSs) that can target tumor cells and generate high levels of reactive oxygen species (ROS). Novel bifunctional Ir(III) complexes have been developed as trackable PSs agents, with complex 4 showing dual emissive patterns and effective accumulation in mitochondria for potential cancer treatment. Activation of these complexes with different light wavelengths can lead to therapeutic effects and enhanced sensitivity in lung cancer cells.
Article
Biochemistry & Molecular Biology
Guillermo Canudo-Barreras, Lourdes Ortego, Anabel Izaga, Isabel Marzo, Raquel P. Herrera, M. Concepcion Gimeno
Summary: The study found that gold complexes are more cytotoxic than silver compounds, with gold complexes showing better cytotoxic effects on cancer cells. The ancillary ligand bound to the metal plays a crucial role in the cytotoxic activity of the complexes, with the bis(thiourea) complex being the most active species.
Review
Cell Biology
Chantal Reina-Ortiz, David Giraldos, Gemma Azaceta, Luis Palomera, Isabel Marzo, Javier Naval, Martin Villalba, Alberto Anel
Summary: NK cell-based therapies show promise as anticancer treatments. The review compares autologous and allogeneic NK cell treatments for MM and their combination with existing therapies. The placement of these treatments in clinical regimens is discussed based on patient immune profiles.
Article
Chemistry, Applied
Andres Luengo, Isabel Marzo, Vanesa Fernandez-Moreira, M. Concepcion Gimeno
Summary: In this study, five heterobimetallic Re-I/Au-I species and one tri-metallic Re-I/Au-I/Re-I species were synthesized and fully characterized. The resultant complexes exhibited luminescence in the orange region, and the emission properties were found to be associated with the electronic properties of the gold ancillary ligand. Antiproliferative activity studies showed that only complex 4, containing a specific gold ancillary ligand, exhibited cytotoxicity in lung and cervical cancer cells.
APPLIED ORGANOMETALLIC CHEMISTRY
(2022)
Review
Pharmacology & Pharmacy
Olaia Akesolo, Berta Buey, Manuel Beltran-Visiedo, David Giraldos, Isabel Marzo, Eva Latorre
Summary: Despite biomedical improvements, multiple myeloma remains incurable. Dysregulated signalling of Toll like receptors (TLRs) may play a critical role in its progression. Strategic targeting of TLRs could improve treatment response and reduce relapses.
BIOCHEMICAL PHARMACOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Patricia Guerrero-Ochoa, Raquel Ibanez-Perez, German Berbegal-Pinilla, Diederich Aguilar, Isabel Marzo, Francisco Corzana, Martha Minjarez-Saenz, Javier Macias-Leon, Blanca Conde, Javier Raso, Ramon Hurtado-Guerrero, Alberto Anel
Summary: Two granulysin-based immunotoxins (SM3GRNLY and AR20.5GRNLY) were generated to target and induce cell death in Tn antigen-expressing tumor cells. The immunotoxins demonstrated stronger cell-killing effects compared to GRNLY alone and induced cell death through apoptotic, necroptotic, and necrotic mechanisms. In a xenograft model, the immunotoxins showed tumor-targeting ability and significantly reduced tumor volume. These findings highlight the potential of these immunotoxins as drugs for Tn-expressing cancers.
Article
Biochemistry & Molecular Biology
Ruth Soler-Agesta, Patricia Guerrero-Ochoa, Joaquin Marco-Brualla, Raquel Ibanez-Perez, Isabel Marzo, Luis Martinez-Lostao, Alberto Anel
Summary: This study developed lipid nanoparticles that can enhance the cytotoxicity of recombinant granulysin, and demonstrated that the mitochondrial apoptotic pathway is the main mechanism of cell death induced by the nanoparticle.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Alfonso Serrano Del Valle, Manuel Beltran-Visiedo, Victoria de Poo-Rodriguez, Nelia Jimenez-Alduan, Gemma Azaceta, Rosana Diez, Beatriz Martinez-Lazaro, Isabel Izquierdo, Luis Palomera, Javier Naval, Alberto Anel, Isabel Marzo
Summary: Immunogenic cell death (ICD) is an important process for antitumor immunosurveillance, characterized by the exposure and emission of Damage Associated Molecular Patterns (DAMP) such as calreticulin (CRT). In certain cancers, high levels of CRT have been found to be associated with improved immune surveillance and better patient prognosis. This study evaluated CRT levels in CD38(+) bone marrow mononuclear cells (BMMCs) of multiple myeloma (MM) patients and found that increased cell surface-CRT levels were associated with aggressive clinical features and worse prognosis in MM.
Article
Chemistry, Multidisciplinary
Maria Gil-Moles, M. Elena Olmos, Miguel Monge, Manuel Beltran-Visiedo, Isabel Marzo, Jose M. Lopez-de-Luzuriaga, M. Concepcion Gimeno
Summary: Silver complexes with substituted terpyridine or tetra-2-pyridinylpyrazine ligands were synthesized and characterized. Despite the potential of combining metal properties and ligand's ability for DNA binding, studies on the anticancer properties of these silver complexes are limited. This study investigated the antiproliferative activity, stability, CT-DNA binding, and mechanism of cell death of these derivatives. The results showed high cytotoxicity against different tumor cells and a notable selectivity index between tumor cells and healthy lymphocytes T for certain compounds. The derivatives were found to moderately intercalate with CT-DNA and promote apoptosis through a mitochondrial pathway.
CHEMISTRY-A EUROPEAN JOURNAL
(2023)
Article
Cell Biology
Oscar Gonzalo, Andrea Benedi, Laura Vela, Alberto Anel, Javier Naval, Isabel Marzo
Summary: Evasion of apoptosis is a hallmark of cancer cells, which involves alterations in Bcl-2 family proteins. The BiFC technique was used to study interactions between different Bcl-2 family members in living cells, revealing a complex network of interactions. Differences in the regulation of Bax and Bak activation by antiapoptotic and BH3-only proteins were observed. Mutations lacking the BH3 domain did not affect the association between Bax and Bak, suggesting alternative surfaces of interaction.
Article
Multidisciplinary Sciences
Nerea Allende-Vega, Joaquin Marco Brualla, Paolo Falvo, Catherine Alexia, Michael Constantinides, Alexis Fayd'herbe de Maudave, Lois Coenon, Delphine Gitenay, Giulia Mitola, Paul Massa, Stefania Orecchioni, Francesco Bertolini, Isabel Marzo, Alberto Anel, Martin Villalba
Summary: Solid tumor cells have altered metabolism that can protect them from cytotoxic lymphocytes, but metformin can increase tumor cell sensitivity to cytotoxic lymphocytes. Research shows that metformin induces expression of NKG2DL and ICAM-1, promoting binding between lymphocytes and tumor cells, and reducing the growth of human hematological tumor cells.
SCIENTIFIC REPORTS
(2022)